Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - - JAMA Oncol - 2019 Manuscript - Primary - Primary - GI - CALGB-80802
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8) Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary - Preliminary - GI - N0849
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset. Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - GI - NCCTG-N0441
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials André, Thierry , Meyerhardt, Jeffrey , Iveson, Timothy ... - - Lancet Oncol - 2020 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80702
Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048 Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. ... - - J. Clin. Oncol - 2018 Manuscript - Secondary-not-in-original - Primary - Health Outcome - N1048
Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017 Abstract - Primary - Primary - Neuro-Onc - A071101
Development of Clinical Precision Medicine Approaches in Meningiomas: Alliance A071401. Brastianos, Priscilla , Shi, Qian , Santagata, Sandro ... - SNOM - - 2016 Abstract - No-Endpoint - Trial-Description-Only - Neuro-Onc - A071401
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC) Chan, E. , Shi, Q. , Garcia-Aguilar, J. , Wolff, B. G. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2010 Abstract - Secondary - Primary - GI - ACOSOG-Z6041
Innovative estimation of survival using log-normal survival modelling on ACCENT database Chapman, J W , O'Callaghan, C J , Hu, N , Ding, K , Yothers, G A ... - - Br. J. Cancer - 2013 Manuscript - No-Endpoint - Primary - GI - N0441
Comparison of innovative estimation of efficacy to standard using the ACCENT database. Chapman, J. W. , O'Callaghan, C. , Hu, N. , Ding, K. , Yothers, G. A. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - NCCTG-N0441
Predictive and prognostic value of gender in early stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Cheung, W. Y. , Shi, Q. , O'Connell, M. , Cassidy, J. , Blanke, C. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - NCCTG-N0441
The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database Cheung, Winson Y. , Shi, Qian , O'Connell, Michael , Cassidy, James ... - - Clin Colorectal Cancer - 2013 Manuscript - Secondary - Primary - GI - N0441
A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT) Dueck, Amylou C. , Mitchell, S.A. , Rogak, Lauren I. , Ginos, Brenda ... - ISOQOL - Qual Life Res - 2015 Abstract - Secondary - Primary - GI - N1048
Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Foster, N. R. , Qi, Y. , Shi, Q. , Krook, J. E. , Kugler, J. W. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Respiratory - NCCTG-N0424
Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials Foster, Nathan R. , Qi, Yingwei , Shi, Qian , Krook, James E. ... - - Cancer - 2011 Manuscript - Primary - Primary - Respiratory - N0424
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of NCCTGs phase III trials N9741 and N9841. Franko, J. , Shi, Q. , Goldman, C. D. , Pockaj, B. A. , Nelson, G. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Comprehensive - GI - N9841 , N9741
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 Franko, Jan , Shi, Qian , Goldman, Charles D. , Pockaj, Barbara A. ... - - J Clin Oncol - 2012 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9841 , N9741
Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) and local excision (LE) for uT2uN0 rectal cancer (RC): results of the ACOSOG Z6041 trial Garcia-Aguilar, J. , Shi, Q. , Thomas, C. R., Jr , Chan, E. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - GI - ACOSOG-Z6041
Organ preservation for clinical t2n0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision: results of a multicenter phase 2 study Garcia-Aguilar, Julio , Renfro, Lindsay A. , Chow, Oliver S. ... - - Lancet Oncol. - 2015 Manuscript - Primary - Primary - GI - ACOSOG-Z6041
A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial Garcia-Aguilar, Julio , Shi, Qian , Thomas, Charles R. , Chan, Emily ... - - Ann. Surg. Oncol. - 2012 Manuscript - Primary - Preliminary - GI - ACOSOG-Z6041
Variability of Pelvic MRI Performance in a Prospective Multicenter Rectal Cancer Trial NCCTG N1048 (Alliance) Gollub, Marc J. , Shi, Qian , Nougaret, Stephanie ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - N1048
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer Grothey, A. , Sobrero, A.F. , Shields, A.F. , Yoshino, T. , Paul, J. ... - - N. Engl. J. Med. - 2018 Manuscript - Secondary-not-in-original - Primary - GI - CALGB-80702
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration Grothey, Axel , Sobrero, Alberto F. , Meyerhardt, Jeffrey A. ... - ESMO - Annals of Oncology - 2017 Abstract - Secondary-not-in-original - Comprehensive - GI - CALGB-80702
Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set Hubbard, Joleen , Thomas, David M. , Yothers, Greg , Green, Erin ... - - J. Clin. Oncol - 2012 Manuscript - Secondary - Comprehensive - GI - ACCENT , CALGB-89803
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Katz, Matthew H. G. , Ou, Fang-Shu , Herman, Joseph M. ... - - BMC Cancer - 2017 Manuscript - No-Endpoint - Trial-Description-Only - GI - A021501
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Katz, Matthew H. G. , Shi, Qian , Ahmad, Syed A. , Herman, Joseph M. ... - - JAMA Surg - 2016 Manuscript - Primary - Primary - GI - A021101
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. Katz, Matthew H.G. , Shi, Qian , Ahmad, Syed , Herman, Joseph ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary - Primary - GI - A021101
Borderline resectable pancreatic cancer: Need for Standardization and Methods for Optimal Clinical Trial Design Katz, Matthew HG , Marsh, Robert , Herman, Joseph M. , Shi, Qian ... - - Ann. Surg. Oncol. - 2013 Manuscript - No-Endpoint - Comprehensive - GI - A021101
Alliance trial A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas Katz, Matthew , Shi, Qian , Meyers, Jeff , Herman, Joseph M. ... - ASCO GI - J Clin Oncol - 2021 Abstract - Primary - Primary - GI - A021501
Genetic predictors of severe skin toxicity in stage III colon cancer patients treated with cetuximab: NCCTG N0147 (Alliance) Labadie, Julia D. , Hua, Xinwei , Harrison, Tabitha A. ... - - Cancer Epidemiol Biomarkers Prev - 2021 Manuscript - Secondary-not-in-original - Primary - PPP - N0147
Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147 Lee, A. , Shi, Q. , Pavey, E. , Sargent, D. J. , Alberts, S. R. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) as predictors of toxicity in Stage III colon cancer (CC) patients (pts) (NCCTG N0147) (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - Correl Sci NOS - N0147
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - - Pharmacogenet. Genomics - 2016 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147) Lee, Adam M. , Shi, Qian , Pavey, Emily , Alberts, Steven R. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance) Lee, H. , Sha, D. , Foster, N. R. , Shi, Q. , Alberts, S. R. ... - - Ann. Oncol. - 2020 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Association of micropapillary architecture and high tumor budding with prognosis in patients with stage III colon cancer from a FOLFOX-based adjuvant chemotherapy trial: NCCTG N0147 (Alliance) Lee, Hee Eun , Shi, Qian , Foster, Nate , Chan, Emily , Gill, Sharlene ... - USCAP - Mod Pathol - 2017 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Rural and urban disparities based on zip code of residence: Analyses of 834 and 2159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively Malla, Midhun , Huebner, Luke J , Piawah, Sorbarikor ... - ASCO - JCO - 2020 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405 , N9741
Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702 Meyerhardt, Jeffrey A. , Shi, Qian , Fuchs, Charles S. ... - ASCO - JCO - 2020 Abstract - Primary - Primary - GI - CALGB-80702
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. Meyerhardt, Jeffrey A , Shi, Qian , Fuchs, Charles S , Meyer, Jeffrey ... - - JAMA - 2021 Manuscript - Primary - Primary - GI - CALGB-80702
Genetic correlates of therapeutic toxicities of stage III colon cancer (CC) patients treated with adjuvant FOLFOX+/-cetuximab (Alliance NCCTG N0147) Newcomb, Polly A. , Sun, Wei , Hua, Xinwei , Banbury, Barbara ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary - Primary - PPP - NCCTG-N0147
Milestone prediction for time-to-event endpoint monitoring in clinical trials Ou, Fang-Shu , Heller, Martin ... - - Pharm Stat - 2019 Manuscript - No-Endpoint - Other - GI - A151730
Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer Penney, Kathryn L. , Banbury, Barbara L. , Bien, Stephanie ... - - Clin. Gastroenterol. Hepatol. - 2019 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Genome-wide association with survival in stage II-III colon cancer (CC) clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology) Penney, Kathryn , Banbury, Barbara L. , Shi, Qian ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - PPP - N0147
Smoking status and prognosis in patients with stage III colon cancer: A correlative analysis of NCCTG phase III trial N0147 Phipps, A. I. , Shi, Q. , Limburg, P. L. J. , Nelson, G. D. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary - Primary - GI - N0147
Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147 Phipps, A. I. , Shi, Q. , Newcomb, P. A. , Nelson, G. D. ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary - Primary - GI - N0147
Pre-diagnostic physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance) Phipps, Amanda I. , Shi, Qian , Chan, Emily , Gill, Sharlene ... - ASPO - - 2017 Abstract - Secondary - Primary - GI - NCCTG-N0147
Alcohol consumption and colon cancer prognosis among participants in North Central Cancer Treatment Group phase III trial N0147 Phipps, Amanda I. , Shi, Qian , Limburg, Paul J. , Nelson, Garth D. ... - - Int. J. Cancer - 2016 Manuscript - Secondary - Primary - GI - N0147
Alcohol consumption and prognosis in patients with stage III colon cancer: a correlative analysis of NCCTG phase III trial N0147 Phipps, Amanda I. , Shi, Qian , Limburg, Paul J. , Nelson, Garth D. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - GI - N0147
Physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance) Phipps, Amanda I. , Shi, Qian , Zemla, Tyler J. , Dotan, Efrat ... - - Cancer Epidemiol. Biomarkers Prev. - 2018 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N0147
Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803. Sargent, D. J. , Yothers, G. , Van Cutsem, E. , Cassidy, J. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Meta-Analysis - GI - CALGB-89803
Two or Three Year Disease Free Survival (DFS) as a Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with fluoropyrimidines with or without Oxaliplatin or Irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803 Sargent, D , Shi, Q , Yothers, G , Van Cutsem, E , Cassidy, J ... - - Eur J Cancer - 2011 Manuscript - Secondary-not-in-original - Comprehensive - GI - C89803
Challenges and Solutions in the Design and Execution of the PROSPECT Phase II/III Neoadjuvant Rectal Cancer Trial (NCCTG N1048/Alliance) Schrag, Deborah , Weiser, Martin , Saltz, Leonard , Mamon, Harvey ... - - Clin Trials - 2019 Manuscript - Secondary-not-in-original - Primary - GI - N1048
Tumor infiltrating lymphocytes and tumor budding refine prognostication in patients with low and high risk stage III colon cancers (NCCTG N0147)[Alliance] Sha, D. , Lee, H. , Foster, N.R. , Shi, Q. , Alberts, S.R. ... - ASCO - J Clin Oncol - 2020 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0147
Association study of the let-7 miRNA-complementary site variant in the 3’ untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 clinical trial) Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - - Clin. Cancer Res. - 2014 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Association study of the let-7 microrna-binding site polymorphism in 3-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147 Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database. Shi, Q. , Hubbard, J. M. , Yothers, G. A. , Andre, T. , Saltz, L. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0441
Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database Shi, Qian , Andre, Thierry , Grothey, Axel , Yothers, Greg ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary-not-in-original - Meta-Analysis - GI - CALGB-89803 , NCCTG-784852 , NCCTG-874651 , NCCTG-894651 , NCCTG-914653
Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration (Alliance) Shi, Qian , Sobrero, Alberto , Shields, Anthony , Yoshino, Takayuki ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80702
Cancer registries: a novel alternative to long-term clinical trial follow-up based on results of a comparative study Shi, Qian , You, Y Nancy , Nelson, Heidi , Allen, Mark S ... - - Clin Trials - 2010 Manuscript - Secondary-not-in-original - Primary - Respiratory - ACOSOG-Z0030
Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: the IDEA collaboration Shields, Anthony F. , Ou, Fang-Shu , Paul, James ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80702
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance) Singh, Preet Paul , Shi, Qian , Foster, Nathan R. , Grothey, Axel ... - - Oncologist - 2016 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N0147
Relationship between Metformin use and Recurrence and Survival in Patients (pts) with Resected Stage III Colon Cancer (CC) Receiving Adjuvant Chemotherapy: Results from NCCTG N0147 (Alliance) Singh, Preet Paul , Shi, Qian , Foster, Nathan , Grothey, Axel ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - GI - N0147
Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC, Alliance A021502) Sinicrope, FA , Ou, F-S , Shi, Q , Nixon, A , Mody, Kabir ... - ASCO - J. Clin. Oncol. - 2017 Abstract - No-Endpoint - Trial-Description-Only - GI - A021502
Prognostic Variables in Low and High Risk Stage III Colon Cancers Treated in Two Adjuvant Chemotherapy Trials Sinicrope, Frank A. , Chakrabarti, Sakti , Laurent-Puig, Pierre ... - - Eur J Cancer - 2021 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Relative Contribution of Clinical and Molecular Features to Outcome Within Low and High Risk T and N Groups in Patients with Stage III Colon Cancers (Alliance) Sinicrope, Frank A. , Huebner, Luke , Laurent-Puig, Pierre ... - ASCO - JCO - 2019 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS with Survival after Recurrence in Stage III Colon Cancers from Phase III Adjuvant Chemotherapy Trials Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen J. ... - - JAMA Oncol - 2017 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen Joseph ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ESMO GI - Annals of Oncology - 2017 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ASCO GI - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Association of an immunoscore with survival of stage III colon cancer (CC) patients treated with adjuvant FOLFOX (Alliance N0147) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne , Heying, Erica ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant therapy trial: NCCTG N0147 (Alliance) Sinicrope, Frank A. , Shi, Qian , Lee, Hee Eun , Foster, Nathan R. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy (NCCTG N0147) (Alliance) Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - - Gastroenterology - 2015 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)]. Sinicrope, Frank A. , Shi, Qian , Thibodeau, Stephen N. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary - Primary - Correl Sci NOS - N0147
Association Of Tumor Infiltrating Lymphocytes (Tils) With Molecular Subtype And Prognosis In Stage III Colon Cancers From A FOLFOX-Based Adjuvant Chemotherapy Trial: NCCTG N0147 (Alliance) Sinicrope, Frank A. , Smyrk, Thomas C. , Foster, Nathan R. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147
Mutation-Specific Antibody Detects Mutant BRAFV600E Protein Expression in Human Colon Carcinomas Sinicrope, Frank A. , Smyrk, Thomas C. , Tougeron, David ... - - Cancer - 2013 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer Sinicrope, Frank A , Shi, Qian , Hermitte, Fabienne , Zemla, Tyler J ... - - JNCI Cancer Spectr - 2020 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147). Sloan, J. A. , Shi, Q. , Lee, A. , Diasio, R. B. , Pavey, E. S. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - Health Outcome - NCCTG-N0147
Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody Smyrk, T. C. , Tougeron, D. , Thibodeau, S. N. , Singh, S. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Overall survival (OS) of comparing 3 vs 6 months of adjuvant (adjuv) oxaliplatin-based therapy for patients (pts) with stage III colon cancer (CC): Updated results from the IDEA (International Duration Evaluation of Adjuv chemotherapy) collaboration Sobrero, Alberto F. , Thierry, Andre , Meyerhardt, Jeffrey A. ... - ASCO - J Clin Oncol - 2020 Abstract - Secondary - Primary - GI - CALGB-80702
Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance) Song, Mingyang , Ou, Fang-Shu , Zemla, Tyler J. , Hull, Mark A. ... - - Int. J. Cancer - 2019 Manuscript - Secondary-not-in-original - Primary - GI - N0147
Postdiagnosis marine omega-3 fatty acid intake and survival of stage III colon cancer in North Central Cancer Treatment Group phase III trial N0147 (Alliance) Song, Mingyang , Ou, Fang-Shu , Zemla, Tyler J. , Shi, Qian ... - DDW - Gastroenterology - 2018 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0147
Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes Sprangers, Mirjam A. G. , Sloan, Jeff A. , Barsevick, Andrea ... - - Qual Life Res - 2010 Manuscript - Secondary-not-in-original - Comprehensive - Health Outcome - N9741
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer Taieb, Julien , Le Malicot, Karine , Shi, Qian ... - - J. Natl. Cancer Inst - 2016 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials Taieb, Julien , Malicot, Karine Le ... - ASCO - J Clin Oncol - 2015 Abstract - Secondary-not-in-original - Comprehensive - Correl Sci NOS - N0147
Perioperative gemcitabine + erlotinib plus pancreaticoduodenectomy for resectable pancreatic adenocarcinoma: ACOSOG Z5041 (Alliance) phase II trial Wei, Alice C. , Ou, Fang-Shu , Shi, Qian , Carrero, Xiomara ... - - Ann. Surg. Oncol. - 2019 Manuscript - Primary - Primary - GI - ACOSOG-Z5041
A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG/ Alliance Z5041 Trial Wei, Alice Chia-chi , Ou, Fang-Shu , Shi, Qian ... - ASCO - J. Clin. Oncol - 2018 Abstract - Primary - Primary - GI - ACOSOG-Z5041
Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) Wilcox, Ryan E. , Shi, Qian , Sinicrope, Frank A. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - Correl Sci NOS - N0147
Deletions in HSP110 T17 and Patient Prognosis in Stage III Microsatellite Instable (MSI) Colon Cancers: Findings from CALGB 89803 and NCCTG N0147. Wu, Christina , Shi, Qian , Tomsic, Jerneja , Meyers, Jeffrey ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-89803 , NCCTG-N0147
Prognostic impact of specific KRAS mutations in codon 12 and 13 in 2,165 BRAF-wildtype colon cancers: Results from NCCTG N0147 (Alliance) Yoon, H. H. , Tougeron, D. , Mahoney, M. R. , Shi, Q. , Sargent, D. J. ... - - European Journal of Cancer - 2013 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients Yoon, Harry H. , Shi, Qian , Alberts, Steven R. ... - - J. Natl. Cancer Inst - 2015 Manuscript - Secondary-not-in-original - Primary - GI - N0147
Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]). Yoon, Harry H. , Shi, Qian , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - GI - N0147
Inter-tumoral heterogeneity of CD3+ and CD8+ T-cell densities in the microenvironment of DNA mismatch repair-deficient colon cancers: implications for prognosis Yoon, Harry H. , Shi, Qian , Heying, Erica N. , Muranyi, Andrea ... - - Clin. Cancer Res. - 2019 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance) Yoon, Harry H. , Shi, Qian , Heying, Erica N. , Muranyi, Andrea ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance) Yoon, Harry H. , Tougeron, David , Shi, Qian , Alberts, Steven R. ... - - Clin. Cancer Res. - 2014 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - - JCO Precis Oncol - 2020 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - - JAMA Oncol - 2018 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - ASCO - J Clin Oncol - 2019 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX + cetuximab in the PETACC8 and N0147 adjuvant trials. Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set de Gramont, Aimery , Hubbard, Joleen , Shi, Qian ... - - J Clin Oncol - 2010 Manuscript - Secondary - Primary - GI - N9741
